ResMed Inc. (RMD) earnings on August 6, 2026
Prior outlook: Optimistic Outcome: Missed
ResMed's stock fell after its earnings report, dropping as much as 10.9% during the day and closing down 5.2%. This happened despite mixed analyst opinions, with one firm raising its price target and another lowering it.
RMD price around the earnings
211.94
Change: -5.1%
2026-08-07, 20:00 UTC
Start of the measured window
End of the measured window
197.99
206.85
215.71
224.57
223.41
August 6, 2026
August 7, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Missed
- Thesis published
- Results released
Strong historical beats and positive growth outlook, but recent analyst downgrades temper the pre-earnings trend strength.
Context analyzed before publication
- Trend
- Stock shows strong positive trend strength into earnings, despite some recent volatility and analyst downgrades.
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 2.39
- Analysts covering the stock
- 15
- Average price target
- 248.53
- Lowest price target
- 180
- Highest price target
- 325
- Upside to price target
- 11.7%
- Quarterly earnings growth
- 9.2%
- Revenue growth
- 10.8%
- Forward EPS
- 12.08
- Trailing EPS
- 10.37
- Analyst moves in the last 60 days
- 8
- Strong buy: 1
- Buy: 6
- Hold: 10
- Sell: 1
- Strong sell: 0
- Strong buy
- 1
- Buy
- 6
- Hold
- 10
- Sell
- 1
- Strong sell
- 0
- July 15, 2026 · Mizuho: Maintains rating (Outperform → Outperform)
- July 13, 2026 · Citigroup: Downgrades rating (Buy → Neutral)
- July 10, 2026 · Jefferies: Maintains rating (Hold → Hold)
- July 8, 2026 · RBC Capital: Maintains rating (Outperform → Outperform)
- July 8, 2026 · Wells Fargo: Maintains rating (Equal-Weight → Equal-Weight)
- June 22, 2026 · Keybanc: Maintains rating (Overweight → Overweight)
- June 17, 2026 · Morgan Stanley: Downgrades rating (Overweight → Equal-Weight)
- June 15, 2026 · Citigroup: Maintains rating (Buy → Buy)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
News
Sources (8)
- Mizuho Maintains Outperform on ResMed, Lowers Price Target to $220 (opens in a new tab) — Benzinga
- Citigroup Downgrades ResMed to Neutral, Lowers Price Target to $235 (opens in a new tab) — Benzinga
- Jefferies Maintains Hold on ResMed, Lowers Price Target to $225 (opens in a new tab) — Benzinga
- ResMed Analyst Backs Portfolio Reset (opens in a new tab) — Benzinga
- RBC Capital Maintains Outperform on ResMed, Lowers Price Target to $276 (opens in a new tab) — Benzinga
- Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $225 (opens in a new tab) — Benzinga
- ResMed Says Deal Valued At $490M All-Cash, Expected To Close In Q1 FY2027 (opens in a new tab) — Benzinga
- Resmed Strikes Agreement To Sell Its MatrixCare Operations To Frazier Healthcare Partners; Financial Terms Undisclosed (opens in a new tab) — Benzinga
Technicals
Evidence
- Price when the context was analyzed
- 224.12
- Average true range (ATR)
- 2.9%
- Distance to 52-week high
- -23.6%
- 14-day change (14d)
- +16.0%
- 30-day change (30d)
- +2.6%
- 30-day relative strength
- +0.1%
- SPY change (30d)
- +2.5%
- Nearest support
- 223.62
- Distance to nearest support
- 0.2%
- Nearest resistance
- 225.09
- Distance to nearest resistance
- 0.4%
- Volume accumulation ratio (14d / 46d)
- 0.9
- Mid: 223.62 (0.2% away, 0.08 ATR, 19 touches)
- Mid: 222.43 (0.8% away, 0.26 ATR, 17 touches)
- Mid: 221.08 (1.4% away, 0.46 ATR, 16 touches)
- Major: 225.09 (0.4% away, 0.15 ATR, 34 touches)
- Major: 226.97 (1.3% away, 0.43 ATR, 20 touches)
- Major: 230.04 (2.6% away, 0.9 ATR, 23 touches)
Trends
Evidence
- Average earnings surprise
- +2.5%
- April 30, 2026: actual EPS 2.86 vs estimate 2.8 (surprise +2.1%)
- January 29, 2026: actual EPS 2.81 vs estimate 2.72 (surprise +3.1%)
- October 30, 2025: actual EPS 2.55 vs estimate 2.5 (surprise +2.0%)
- July 31, 2025: actual EPS 2.55 vs estimate 2.48 (surprise +2.8%)
Expected move
- Implied move
- +3.1%
- Source
- Options chain
Reactions over its last 20 earnings
- Median move
- 4.1%
- 75th percentile move
- 7.4%
- 90th percentile move
- 10.8%
- Up / down moves
- 9 / 11
- Average up move
- +6.8%
- Average down move
- -5.3%
Monitoring and close
What ResMed Inc. reported
- Status
- Finished
| Actual EPS | 2.95 |
|---|---|
| EPS estimate | 2.89 |
| EPS surprise | +2.1% |
| Revenue | $1,464 million |
| Revenue estimate | $1,459 million |
| Revenue surprise | +0.3% |
ResMed beat expectations in Q4 with adjusted earnings of $2.95 per share and record sales of $1.464 billion. The company raised its quarterly dividend to $0.66 per share.
Sources (6)
- ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops (opens in a new tab) — StockStory
- ResMed (NYSE:RMD) Q4 Results Inline with Estimates; Stock Slips 1.9% (opens in a new tab) — ChartMill
- Resmed Raises Quarterly Dividend From $0.60 To $0.66/Share (opens in a new tab) — Benzinga
- ResMed beat expectations with adjusted earnings of $2.95 per share and sales of $1.464 billion, above forecasts. — Benzinga
- ResMed Q4 Adj. EPS $2.95 Beats $2.89 Estimate, Sales $1.464B Beat $1.459B Estimate (opens in a new tab) — Benzinga
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026 (opens in a new tab) — Yahoo
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, results beat expectations on both earnings and revenue, and the price is indicating -11.3% pre-market, a move 3x the stock's usual reaction (about 4%). The figures overturn the prior optimistic scenario. In the 744 similar cases in our market history, the close held that direction 96% of the time.
How the stock reacted
- Outcome
- Missed
- Consolidated
- -5.2%
- Max favorable move (MFE)
- 0.2%
- Max adverse move (MAE)
- 10.9%